The next CCC-Excellence will be on lung Cancer. Paul A. Bunn will present the latest developments and findings in the fields of early detection, prevention and treatment of lung cancer. His talk’s title is: “Lung Cancer: early detection, prevention and treatment in 2018”
Wednesday, 23rd May 2018, 4 pm at CeMM, Seminar Room on level 8.
Paul A. Bunn, Jr. is Distinguished Professor and the James Dudley Chair in Cancer Research in the Division of Medical Oncology at the University of Colorado Cancer Center of the University of Colorado School of Medicine, where he has practiced and taught since 1984.
He received his B.A. from Amherst College in Amherst, Massachussets, and received his M.D. from Weill Cornell Medical College in New York City. He completed an internship and residency at the University of California San Francisco and a fellowship in medical oncology at the National Cancer Institute (Bethesda) Program. He is board certified in internal medicine and medical oncology. Paul Bunn served as the Head of the Division of Medical Oncology from 1984-1992 and as the Director of the University of Colorado Cancer Center from 1986-2009. In the IASLC, Bunn served on the Board of Directors from 1988 to 1994, as president from 1997-2000, and as CEO from 2004-2014. Dr. Bunn was the president of ASCO from 2002-2003.
As an author of hundreds of articles, reviews and book chapters, his research is well known in the cancer world. He focuses primarily on novel therapies for lung cancer. Paul Bunn has led numerous national and local trials regarding the treatment of lung cancer, and his findings are credited with setting standards in the treatment of the disease.
Bunn has researched new personalized therapiesfor lung cancer thatcause fewer side effects than traditional, intravenous chemotherapy. He has also studied the genetics of the disease, seeking to learn how gene therapy could be used to combat the disease. He is currently the Principal Investigator on the Specialized Program in Research Excellence in Lung Cancer (SPORE) grant funded by the National Institutes of Health and theNational Cancer Institutethat aims to expand understanding about the biology of the disease, as well as to find new methods of diagnosis, prevention and treatment.
The event will be approved by the Austrian Medical Chamber with 1 DFP-Point.